Phase IbII Study of Cabozantinib and Dostarlimab Treatment in Women with Recurrent Gynecologic Carcinosarcoma

What this Trial Is About

Researchers are investigating a combination treatment for women with recurrent gynecologic carcinosarcoma, a type of cancer affecting female reproductive organs. This study explores the effects of combining Cabozantinib, a drug that blocks vascular endothelial growth factors VEGF, with Dostarlimab, an immunotherapy drug. This combination is being studied to understand if it can improve the bodys immune response against cancer, as VEGF inhibitors might help enhance the function of cells that present cancer antigens to the immune system. Participants will receive Cabozantinib at a dose of 40 mg taken orally every day along with Dostarlimab given intravenously at 500 mg every 3 weeks for the first four treatment cycles. After this initial phase, maintenance therapy will continue with Cabozantinib 40 mg daily and Dostarlimab 1000 mg every 6 weeks. This treatment will continue for up to two years or until disease progression or unacceptable side effects. During the study, women will be closely monitored through regular assessments to measure how long their cancer remains stable without worsening, specifically focusing on progression-free survival at 6 months. Participants will undergo laboratory tests to ensure adequate organ function and will be evaluated for side effects and overall health. The total duration of participation depends on individual response and treatment tolerance, with ongoing safety monitoring throughout the study period.

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma